BioSyntech, Inc. has inked a scientific collaboration with their biopharmaceutical partner Nicholas Piramal. This collaboration will involve Clinical studies for BST-InPod, which is being developed to alleviate the chronic pain associated with foot fat pads. This collaboration will help to generate more clinical data at a lower cost in India.

Chronic heel pain is widespread according to the American College of Foot and Ankle Surgeons reports. The Heel pain is a complaint voiced by 14 percent of the adult population and suspects that millions more silently cope with it. Injected directly into the fat pad, BST-InPod is expected to result in a long-term reduction in pain by improving the biomechanical function of the treated fat pad.

BioSyntech is a biotechnology company specializing in the discovery, development, and manufacturing of innovative, cost-effective, and physician-friendly therapeutic thermogels for regenerative medicine and therapeutic delivery.

Nicholas Piramal, with strong brand management and sales capabilities, has a FDA approved plant for on-and-off patent APIs and Intermediates. It has R&D capabilities in Basic Research, Process Innovation, Custom Chemical Synthesis, Formulations R&D, NDDS, and also has a world-class accredited Clinical Research Organisation.